The protective effects of astaxanthin against cisplatin-induced retinal toxicity

Findik H., Tumkaya L., Yilmaz A., Aslan M. G., Okutucu M., Akyildiz K., ...More

CUTANEOUS AND OCULAR TOXICOLOGY, vol.38, no.1, pp.59-65, 2019 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 38 Issue: 1
  • Publication Date: 2019
  • Doi Number: 10.1080/15569527.2018.1518330
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.59-65
  • Keywords: Astaxanthin, chemotherapy, cisplatin toxicity, eNOS, oxidative stress, retina, OXIDATIVE STRESS, NITRIC-OXIDE, IN-VITRO, INDUCED NEPHROTOXICITY, DOSE CISPLATIN, CANCER, LIVER, HEPATOTOXICITY, CAROTENOIDS, 8-OHDG
  • Recep Tayyip Erdoğan University Affiliated: Yes


Purpose: This study investigated the toxic effects of an antineoplastic agent, cisplatin (CIS), on retinal cells and the potential capacity of astaxanthin (ASTA) to elicit a future therapeutic protocol in CIS-induced retinal toxicity. Materials and methods: Six groups were formed for the assessment; control (healthy; Group 1), olive oil (olive oil only; Group 2), ASTA control group (ASTA only, Group 3), the single intraperitoneal (IP) dose of 16 mg/kg CIS (CIS only group; Group 4), 16 mg/kg CIS +25 mg/kg (IP) ASTA (Group 5), and 16 mg/kg CIS +75 mg/kg (IP) ASTA (Group 6). On the third day after CIS administration, rats in all groups were sacrificed under anesthesia and the analysis of the biochemical parameters and histopathological levels were performed. Results: A significant decrease in GSH levels and increases in MDA, eNOS, and 8-OHdG expressions were recorded. Additionally, CIS treatment had caused acidophilic staining in retinal histological appearance. ASTA treatment reduced the increases in MDA, eNOS, and 8-OHdG levels following CIS administration and increased the levels of GSH expressions, as well. Conclusions: These results may suggest that the ASTA molecule as a promising option to prevent retinal toxicity in patients receiving CIS treatment for malignant tumors.